Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Afterword.

Brice Gayet1, David Fuks1

  • 1Department of Digestive, Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Université Paris Descartes, 42 Boulevard Jourdan, Paris 75014, France.

Surgical Oncology Clinics of North America
|March 11, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From dysphagia to kidney disease: Alport syndrome with leiomyomatosis.

Kidney international·2026
Same author

The impact of tumor location on oncologic outcomes in laparoscopic parenchymal sparing resection of colorectal liver metastases.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same author

Short-term outcomes of laparoscopic versus open major hepatectomy for benign liver disease: an international bicentric study.

Langenbeck's archives of surgery·2026
Same author

Study-International Multicentric Minimally Invasive Liver Resection (SIMMILR-5): A Comparison of Open, Conventional Laparoscopic and Tele-Robotic Laparoscopic Liver Resection for Hepatocellular Cancer.

Cancers·2026
Same author

Conversion in Minimally Invasive Liver Surgery: The Impact of Conversion Urgency and Surgical Approach.

Annals of surgical oncology·2026
Same author

Validation of the Institute Mutualiste Montsouris system for the stratification of laparoscopic liver resections: an international multicenter study.

Hepatobiliary surgery and nutrition·2026
Same journal

Small Incisions, Big Impact-Robotic Surgery Is Revolutionizing Cancer Care.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Cancer.

Surgical oncology clinics of North America·2026
Same journal

TeleSurgery: The Present and the Future for Minimally Invasive and Robotic Surgery.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Rectal Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery in Liver Transplantation.

Surgical oncology clinics of North America·2026
See all related articles

Surgical removal of solid tumors remains the primary cancer treatment. Neoadjuvant therapies aim to shrink tumors or prevent relapse before surgery, improving patient outcomes.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Cancer Treatment

Background:

  • Multimodality cancer treatment has advanced significantly.
  • Surgery remains the cornerstone of curative intent for solid tumors.
  • Neoadjuvant therapies (chemotherapy, radiation) precede surgical tumor removal.

Purpose of the Study:

  • To emphasize the continued reliance on surgical tumor removal for cancer cure.
  • To highlight the role of neoadjuvant treatments in optimizing surgical outcomes.
  • To underscore that healthcare progress prioritizes improved care and cost-effectiveness over mere novelty.

Main Methods:

  • Review of current cancer treatment modalities.
  • Analysis of the role of surgery in solid tumor management.
Keywords:
CancerEsophagectomyHepatectomyLaparoscopySimulation-based trainingTumor

Related Experiment Videos

  • Evaluation of neoadjuvant treatment strategies in conjunction with surgery.

    • Main Results:

    • Surgery is the principal curative treatment for solid tumors.
    • Neoadjuvant treatments effectively reduce tumor burden and systemic relapse risk.
    • Improvements in cancer care are measured by enhanced patient outcomes and cost efficiency.

    Conclusions:

    • Surgical resection remains essential for achieving a cure in solid cancers.
    • Neoadjuvant therapies are critical adjuncts to surgery, improving treatment efficacy.
    • Focus on tangible improvements in patient care and healthcare economics drives progress.